Hayward, CA (PRWEB) April 20, 2012
GenturaDx, a molecular diagnostics company, announced today that it will present a corporate workshop entitled “Applying a New Standard of Molecular Testing to Herpes Simplex Virus,” at the 2012 Clinical Virology Symposium at the Hilton, Daytona Beach, Fla. on Monday, April 23, at 2:45 p.m.
Presenter Keith Jerome, M.D., Ph.D., GenturaDx Scientific Advisory Board member, will focus on the current clinical issues surrounding Herpes Simplex Virus (HSV) genital infections, and Jesus Ching, Ph.D., Chief Scientific Officer and Founder of GenturaDx, will discuss how GenturaDx’s IDbox™ HSV 1/2 test can aid in addressing these issues. Genital HSV is the leading sexually transmitted disease in the United States with over 50 million (1) individuals infected and over 1.6 million (2) new infections per year. Reducing further transmissions by raising awareness through accurate testing is the best method of prevention.
Dr. Jerome will focus on the clinical background of genital HSV and what can be done to reduce the spread of the disease. Dr. Jerome is a widely published expert on HSV and viral infections. He currently serves as the Director of the Molecular Virology Laboratory in the Department of Laboratory Medicine, and as Associate Professor in Laboratory Medicine, at the University of Washington in Seattle. Dr. Jerome is an Associate Editor of Diagnostic Microbiology and Infectious Diseases and on the Editorial Advisory Board of the Journal of Infectious Diseases.
Dr. Ching will present an overview of the IDbox instrument and proprietary cassette, and discuss how the system will address the need for a highly sensitive, rapid, cost-effective and easy-to-use diagnostic test for genital HSV and other infectious diseases. Dr. Ching will also discuss the system features and attributes providing sensitivity, multiplexing capacity, assay and protocol flexibility, and cost effectiveness.
GenturaDx is a molecular diagnostic company focused on developing high-performance molecular diagnostic products that are both affordable and practical for any laboratory. The company is developing the IDbox: a fully integrated, automated instrument that conducts testing using a single-use cassette. This platform will make rapid, high-quality molecular diagnostics accessible to hospitals and patients worldwide – circumventing long-standing barriers of cost, ease of use, and performance. GenturaDx’s compact, self-contained platform incorporates sample preparation with proprietary, real-time PCR amplification and detection. The platform’s unique engineering design and intuitive interface rely on a semi-batch processing capability while improving clinical value by offering multiple molecular targets in a single test. For more information, go to http://www.GenturaDx.com.
1. “Sexually Transmitted Diseases Treatment Guidelines,” CDC; 2010.
2. N. Glass et al., “Screening for Genital Herpes,” AHRQ #05-0573-B; March 2005.